Sareum Holdings (SAR): Discounted equity fundraise
This situation live
SAR Sareum Holdings
26 Oct 2026 · Subscription conditionally raised; admission pending · +0% since
it has conditionally raised approximately £3.2 million (before expenses) through a subscription for 22,807,143 new ordinary shares
Discounted equity fundraise
Subscription conditionally raised; admission pending
OCT29
Next: Admission of shares and result of WRAP Retail Offer in 3 days
Every step · 1
- 26 Oct 2026 Subscription conditionally raised; admission pending – it has conditionally raised approximately £3.2 million (before expenses) through a subscription for 22,807,143 new ordinary shares ↗
What is happening
Sareum Holdings: Discounted equity fundraise – Subscription conditionally raised; admission pending. ['Subscription conditionally raised; admission pending']
- In short
- Sareum paused AIM trading on 8 Oct 2026 to run a fundraise, and on 26 Oct 2026 announced a conditional £3.2m subscription at 14p, a c.49% discount, with warrants. Funds take SDC-1801 to Phase 2-ready and continue neuroscience work. A WRAP retail offer of up to £100k follows. Trading on AIM restored 26 Oct.
- Announced
- 26 Oct 2026 · Subscription conditionally raised; admission pending
- Size
- c.£3.2m before expenses; 22,807,143 new shares; WRAP offer up to £100k
- Price
- 14p per share
- Discount
- c.49% to 27.5p close on 7 Oct 2026
- Warrants
- One per subscription share, 20p exercise price, three years from Admission; rebases if later cash issue is lower
- Use of money
- SDC-1801 to Phase 2-ready, neuroscience programme, working capital with R&D tax credits
- Next milestone
- Admission expected 8.00 a.m. on 29 Oct 2026; final results around 30 Oct 2026
What comes next
Admission of shares and result of WRAP Retail Offer (29 Oct 2026).
Briefing Pro
New to Sareum Holdings? Get up to speed in 2 minutes.
What it does, how it got here, what management promised and delivered – written from its own announcements.
Get the SAR briefing →From the company's own announcements. Not investment advice.
Also at Sareum Holdings
Sareum (AIM: SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.
Sareum Holdings – company page →